>
Floating Energy Assets Explained
What if Iran's next move against Washington is not a missile launch, but a convoy of oil tankers
Artificial Intelligence Could Transform Bank Runs From Hours-Long Crises...
Dubai Just Finished the World's First Permanent Air Taxi Route: Airport to the Marina in Under 1
Doroni Aerospace Raises More than $60m for H1?X Development
After 13 Years Battling Cancer, a 61-Year-Old Brazilian Man Achieved Complete Remission...
Extraterrestrial habitats may rise via Legos of laser-fused moon dust
Battery-only 19-seater puts China in the electric airliner race
Dream Chaser space plane gets landing approval for debut mission in 2027
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever

For the first time, doctors have injected a person with a treatment that will rely on CRISPR gene-editing to treat blindness.
The milestone comes as part of an ongoing clinical trial to evaluate whether the treatment is safe and effective for people with a specific mutation in a single gene; in this case, one that leads to eye disease and vision loss.
CRISPR is a gene-editing tool adapted from the antiviral defense systems of bacteria that can precisely target and cut out short sequences of DNA from longer strands. The technique is being used in ongoing trials to treat cancer and sickle cell anemia by editing human cells outside the body and injecting them into a patient once they've been CRISPR'd; however, this blindness trial is the first that delivers the gene-editing treatment directly into a person's body, NPR reported—specifically, their eye.